drugset
drugset / Trial / NCT06973577

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

NCT06973577 ↗

Phase 3 Completed 315 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety

Timeline

Start
2025-03-26
Primary completion
2026-04-22
Completion
2026-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 328.8 mg —

Indications

anxiety attention deficit-hyperactivity disorder generalized anxiety disorder social phobia